How many new U.S. patents related to Anaphylm™ does AQST report?

The company reports that the United States Patent and Trademark Office has issued two additional U.S. patents related to Anaphylm™. These patents expand the intellectual property coverage around its epinephrine prodrug sublingual film, according to the brief description included in the current report.

Aquestive Therapeutics (AQST) adds two new U.S. patents for Anaphylm™

Filing Impact

(High)

Filing Sentiment

(Neutral)

Form Type

8-K

Rhea-AI Filing Summary

Aquestive Therapeutics, Inc. filed a current report describing new intellectual property protection for its allergy-treatment candidate. The company announced that the United States Patent and Trademark Office has issued two additional U.S. patents related to Anaphylm™, its novel epinephrine prodrug sublingual film. The report also notes that a detailed press release describing these patents is provided as Exhibit 99.1.

8-K Event Classification

2 items: 8.01, 9.01

2 items

Item 8.01 Other Events Other

Voluntary disclosure of events the company deems important to shareholders but not covered by other items.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Understanding 8-K Material Events →

10/08/2025 - 07:23 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): October 8, 2025

Aquestive Therapeutics, Inc.

(Exact name of Registrant as specified in its charter)


Delaware	001-38599	82-3827296
(State or other jurisdiction of incorporation)	(Commission File Number)	(I.R.S. Employer Identification No.)

30 Technology Drive

Warren, NJ 07059

(908) 941-1900

(Address, Including Zip Code, and Telephone Number, Including Area Code, of Registrant’s Principal Executive Offices)

Not Applicable

(Former name or former address, if changed since last report)

________________________________________________________________________________________________________________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:


☐			Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐			Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐			Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐			Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $0.001 per share	AQST	Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).


Emerging growth company			☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐


Item 8.01			Other Events.

On October 8, 2025, Aquestive Therapeutics, Inc. (the “Company”) issued a press release announcing the United States Patent and Trademark Office has issued two additional U.S. patents related to Anaphylm™, the Company’s novel epinephrine prodrug sublingual film. A copy of the Company’s press release is attached as Exhibit 99.1 to this Current Report and incorporated in this Item 8.01 by reference.


Item 9.01			Financial Statements and Exhibits.

(d) Exhibits.


Exhibit Number						Description
99.1						Aquestive Therapeutics, Inc. Press Release, dated October 8, 2025

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


Dated: October 8, 2025	Aquestive Therapeutics, Inc.

	By:	/s/ A. Ernest Toth, Jr
		Name: A. Ernest Toth, Jr.
		Title: Chief Financial Officer

Source: View Original Filing on SEC EDGAR

FAQ

What did Aquestive Therapeutics (AQST) disclose in this 8-K filing?

Aquestive Therapeutics disclosed that the U.S. Patent and Trademark Office issued two additional U.S. patents related to Anaphylm™, its epinephrine prodrug sublingual film. The company also attached a detailed press release as Exhibit 99.1 describing this intellectual property development.

What is Anaphylm™ mentioned in the Aquestive Therapeutics (AQST) filing?

Anaphylm™ is described as Aquestive Therapeutics’ novel epinephrine prodrug sublingual film. It is designed to deliver epinephrine via a film placed under the tongue, and the filing notes that two additional U.S. patents related to this product have been issued by the U.S. Patent and Trademark Office.

Where can investors find more detail on the new Anaphylm™ patents from AQST?

More detail is available in the company’s press release attached as Exhibit 99.1. The 8-K states that this press release, dated October 8, 2025, provides additional information about the two newly issued U.S. patents related to Anaphylm™ and is incorporated by reference.

Does the Aquestive Therapeutics (AQST) 8-K include financial results or earnings data?

This 8-K focuses on intellectual property and does not present earnings data in the excerpt. It primarily announces issuance of two additional U.S. patents tied to Anaphylm™ and references an accompanying press release for further narrative information about this development.

What exhibit is attached to the Aquestive Therapeutics (AQST) 8-K about Anaphylm™?

The filing identifies Exhibit 99.1 as an Aquestive Therapeutics, Inc. press release dated October 8, 2025. That exhibit contains the company’s detailed public announcement regarding the issuance of two additional U.S. patents for its Anaphylm™ epinephrine prodrug sublingual film.